Buy The Decline
Novavax (NVAX) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 million. This was the first time the company has missed on revenue projections since February of 2017.
This has slowed growth in the stock even with good news coming out on their leading ResVax drug program which has had positive testing on 4,636 infants to date. This break in the action may allow